trending Market Intelligence /marketintelligence/en/news-insights/trending/RM-xYhNgYULgk-QdVdhf5A2 content esgSubNav
In This List

Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo in another cancer indication.

The therapy can now be used to fight a certain type of metastatic colorectal cancer that progressed after receiving fluoropyrimidine, oxaliplatin and irinotecan.

The indication was approved under accelerated approval supported by overall response rate and duration of response in a phase 2 trial.

Opdivo is approved for a number of cancers, including lung cancer.